graph EGM comparisons
pembrolizumab alonetitleStandard of Care (SoC)titleKEYNOTE-042 (PDL1>1%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 637/637KEYNOTE-024 (PDL1>50%), 2016 NCT02142738 mNSCLC - L1 - PDL1 positive 154/151KEYNOTE-042 (PDL1>50%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 299/300KEYNOTE-042 (PDL1>20%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 413/405

Pathology:  mNSCLC - L1 - PDL1 positive; 

mNSCLC - L1 - PDL1 positive
KEYNOTE-042 (PDL1>1%), 2019KEYNOTE-024 (PDL1>50%), 2016KEYNOTE-042 (PDL1>50%), 2019KEYNOTE-042 (PDL1>20%), 2019
pembrolizumab alone4T1T1T1T1
Standard of Care (SoC)0T0T0T0T0